

WEST Search History

DATE: Thursday, October 21, 2004

Hide?	Set Name	Query	Hit Count
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L30	L29	9
		<i>DB=PGPB,USPT; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L29	briand-jacques.in.	9
<input type="checkbox"/>	L28	L11 and L27	0
<input type="checkbox"/>	L27	(enzyme and product) with NMR	118
<input type="checkbox"/>	L26	5804390.pn. or 5698401.pn.	2
<input type="checkbox"/>	L25	5804390.pn	0
<input type="checkbox"/>	L24	isotop\$ and l19	1
<input type="checkbox"/>	L23	(1H or 3H or 11B or 13C or 15N or 19F or 29S or 31P) and L22	0
<input type="checkbox"/>	L22	L21	1
<input type="checkbox"/>	L21	chemical adj shift and L19	1
<input type="checkbox"/>	L20	chemical adj shift and L19	898333
<input type="checkbox"/>	L19	20030143757.pn.	1
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L18	6150179.pn.	2
		<i>DB=USPT; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L17	6150179.pn.	1
		<i>DB=EPAB; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L16	WO-9857155-A1.did.	1
<input type="checkbox"/>	L15	WO-9857155-A1.did.	1
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L14	L13 not l10	1
<input type="checkbox"/>	L13	L11 and L12	5
<input type="checkbox"/>	L12	(substrate or ligand) with NMR	1730
<input type="checkbox"/>	L11	NMR with (one adj dimension\$ adj spectr\$ or two adj dimension\$ adj spectr\$ or three adj dimension\$ adj spectr\$)	35
		<i>DB=PGPB,USPT; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L10	L7 and L9	4
<input type="checkbox"/>	L9	NMR with (one adj dimension\$ adj spectr\$ or two adj dimension\$ adj spectr\$ or three adj dimension\$ adj spectr\$)	29
<input type="checkbox"/>	L8	L5 and L7	238

<input type="checkbox"/>	L7	(substrate or ligand) with NMR	1579
<input type="checkbox"/>	L6	l2 and L5	355
<input type="checkbox"/>	L5	NMR with (one adj dimension\$ or two adj dimension\$ or three adj dimension\$)	2019
<input type="checkbox"/>	L4	NMR same (one adj dimension\$ or two adj dimension\$ or three adj dimension\$)	3112
<input type="checkbox"/>	L3	l1 AND L2	1303
<input type="checkbox"/>	L2	(substrate or ligand) same NMR	4300
<input type="checkbox"/>	L1	NMR and (one adj dimension\$ or two adj dimension\$ or three adj dimension\$)	12089

END OF SEARCH HISTORY

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1639MLS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 Jul 12 BEILSTEIN enhanced with new display and select options,
resulting in a closer connection to BABS
NEWS 4 AUG 02 IFIPAT/IFIUDB/IFICDB reloaded with new search and display
fields
NEWS 5 AUG 02 CAplus and CA patent records enhanced with European and Japan
Patent Office Classifications
NEWS 6 AUG 02 The Analysis Edition of STN Express with Discover!
(Version 7.01 for Windows) now available
NEWS 7 AUG 27 BIOCOMMERCE: Changes and enhancements to content coverage
NEWS 8 AUG 27 BIOTECHABS/BIOTECHDS: Two new display fields added for legal
status data from INPADOC
NEWS 9 SEP 01 INPADOC: New family current-awareness alert (SDI) available
NEWS 10 SEP 01 New pricing for the Save Answers for SciFinder Wizard within
STN Express with Discover!
NEWS 11 SEP 01 New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
NEWS 12 SEP 27 STANDARDS will no longer be available on STN
NEWS 13 SEP 27 SWETSCAN will no longer be available on STN

NEWS EXPRESS JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:01:51 ON 21 OCT 2004

=> file medline biosis embase caplus wpids

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'MEDLINE' ENTERED AT 12:02:06 ON 21 OCT 2004

FILE 'BIOSIS' ENTERED AT 12:02:06 ON 21 OCT 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'EMBASE' ENTERED AT 12:02:06 ON 21 OCT 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'CAPLUS' ENTERED AT 12:02:06 ON 21 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 12:02:06 ON 21 OCT 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

=> s nmr and (substrate or ligand or product)
L1 86252 NMR AND (SUBSTRATE OR LIGAND OR PRODUCT)

=> s nmr and (substrate or ligand or enzyme)
L2 64621 NMR AND (SUBSTRATE OR LIGAND OR ENZYME)

=> s l1 and l2
L3 49788 L1 AND L2

=> e briand jacques/in
'IN' IS NOT A VALID EXPAND FIELD CODE FOR FILE 'MEDLINE'
'IN' IS NOT A VALID EXPAND FIELD CODE FOR FILE 'EMBASE'

E1	1	BRIAND J M/IN
E2	20	BRIAND J P/IN
E3	4 -->	BRIAND JACQUES/IN
E4	1	BRIAND JEAN/IN
E5	1	BRIAND JEAN J/IN
E6	19	BRIAND JEAN PAUL/IN
E7	3	BRIAND JEAN PIERRE/IN
E8	8	BRIAND L/IN
E9	3	BRIAND L E/IN
E10	1	BRIAND LAETITIA/IN
E11	3	BRIAND LAURA E/IN
E12	1	BRIAND LOIC/IN

The indicated field code is not available for EXPAND in this file. To see a list of valid EXPAND field codes, enter HELP SFIELDS at an arrow prompt (=>).

=> e briand jacques/au

E1	579	BRIAND J P/AU
E2	1	BRIAND J Y/AU
E3	24 -->	BRIAND JACQUES/AU
E4	1	BRIAND JEAN/AU
E5	1	BRIAND JEAN CLAUDE/AU
E6	11	BRIAND JEAN FRANCOIS/AU
E7	1	BRIAND JEAN J/AU
E8	11	BRIAND JEAN P/AU
E9	305	BRIAND JEAN PAUL/AU
E10	27	BRIAND JEAN PIERRE/AU
E11	12	BRIAND JOEL/AU
E12	18	BRIAND K/AU

=> s e3
L4 24 "BRIAND JACQUES"/AU

=> s l4 and l1
L5 3 L4 AND L1

=> dup rem
ENTER L# LIST OR (END):15
PROCESSING COMPLETED FOR L5
L6 2 DUP REM L5 (1 DUPLICATE REMOVED)

=> t ti l6 1-2

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
TI Mechanism of Inhibition of Cathepsin K by Potent, Selective
1,5-Diacylcarbohydrazides: A New Class of Mechanism-Based Inhibitors of
Thiol Proteases

L6 ANSWER 2 OF 2 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
DUPLICATE 1
TI Design of potent and selective human cathepsin K inhibitors that span the
active site.

=> d ibib abl l6 1-2
'ABL' IS NOT A VALID FORMAT
In a multifile environment, a format can only be used if it is valid
in at least one of the files. Refer to file specific help messages
or the STNGUIDE file for information on formats available in
individual files.
REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):end

=> d ibib abs l6 1-2

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:709526 CAPLUS
DOCUMENT NUMBER: 132:44920
TITLE: Mechanism of Inhibition of Cathepsin K by Potent,
Selective 1,5-Diacylcarbohydrazides: A New Class of
Mechanism-Based Inhibitors of Thiol Proteases

AUTHOR(S): Bossard, Mary J.; Tomaszek, Thaddeus A.; Levy, Mark
A.; Ijames, Carl F.; Huddleston, Michael J.;
Briand, Jacques; Thompson, Scott; Halpert,
Stacie; Veber, Daniel F.; Carr, Steven A.; Meek,
Thomas D.; Tew, David G.

CORPORATE SOURCE: Departments of Molecular Recognition Physical and
Structural Chemistry and Medicinal Chemistry,
SmithKline Beecham Pharmaceuticals, King of Prussia,
PA, 19406, USA

SOURCE: Biochemistry (1999), 38(48), 15893-15902
CODEN: BICHAW; ISSN: 0006-2960

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The nature of the inhibition of thiol proteases by a new class of
mechanism-based inhibitors, 1,5-diacylcarbohydrazides, is described.
These potent, time-dependent, active-site spanning inhibitors include
compds. that are selective for cathepsin K, a cysteine protease unique to
osteoclasts. The 1,5-diacylcarbohydrazides are slow substrates for
members of the papain superfamily with inhibition resulting from slow
enzyme decarbamylation. Enzyme-catalyzed hydrolysis of
2,2'-N,N'-bis(benzyloxycarbonyl)-L-leucinylcarbohydrazide is accompanied
by formation of a hydrazide-containing **product** and a carbamyl-enzyme
intermediate that is sufficiently stable to be observed by mass spectrometry
and **NMR**. Stopped-flow studies yield a saturation limited value of 43

s-1 for the rate of cathepsin K acylation by 2,2'-N,N'-bis(benzyloxycarbonyl)-L-leucinyllcarbohydrazide. Inhibition potency varies among proteases tested as reflected by 2-3 orders of magnitude differences in K_i and k_{obs}/I , but all eventually form the same stable covalent intermediate. Reactivation rates are equivalent for all enzymes tested ($1 + 10^{-4}$ s $^{-1}$), indicating hydrolysis of a common carbamyl-enzyme form. **NMR** spectroscopic studies with cathepsin K and 2,2'-N,N'-bis(benzyloxycarbonyl)-L-leucinyllcarbohydrazide provide evidence of inhibitor cleavage to generate a covalent carbamyl-enzyme intermediate rather than a tetrahedral complex. The **product** Cbz-Leu-hydrazide does not appear enzyme-bound after cleavage in the **NMR** spectra, suggesting that the stable inhibited form of the enzyme is the thioester complex. 1,5-Diacylcarbohydrazides represent a new class of unreactive cysteine protease inhibitors that share a common mechanism of action across members of the papain superfamily. Both S and S' subsite interactions are exploited in achieving high selectivity and potency.

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 2 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 1

ACCESSION NUMBER: 1998:82491 BIOSIS

DOCUMENT NUMBER: PREV199800082491

TITLE: Design of potent and selective human cathepsin K inhibitors that span the active site.

AUTHOR(S): Thompson, Scott K.; Halbert, Stacie M.; Bossard, Mary J.; Tomaszek, Thaddeus A.; Levy, Mark A.; Zhao, Baoguang; Smith, Ward W.; Abdel-Meguid, Sherin S.; Janson, Cheryl A.; D'Alessio, Karla J.; McQueney, Michael S.; Amegadzie, Bernard Y.; Hanning, Charles R.; Desjarlais, Renee L.; **Briand, Jacques**; Sarkar, Susanta K.; Huddleston, Michael J.; Ijames, Carl F.; Carr, Steven A.; Garnes, Keith T.; Shu, Art; Heys, J. Richard; Bradbeer, Jeremy; Zembryki, Denise; Lee-Rykaczewski, Liz; James, Ian E.; Lark, Michael W.; Drake, Fred H.; Gowen, Maxine; Gleason, John G.; Veber, Daniel F. [Reprint author]

CORPORATE SOURCE: Dep. Medicinal Chem., SmithKline Beecham Pharm., 709 Swedeland Road, P.O. Box 1539, King Prussia, PA 19406, USA

SOURCE: Proceedings of the National Academy of Sciences of the United States of America, (Dec. 23, 1997) Vol. 94, No. 26, pp. 14249-14254. print.
CODEN: PNASA6. ISSN: 0027-8424.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 24 Feb 1998

Last Updated on STN: 24 Feb 1998

AB Potent and selective active-site-spanning inhibitors have been designed for cathepsin K, a cysteine protease unique to osteoclasts. They act by mechanisms that involve tight binding intermediates, potentially on a hydrolytic pathway. X-ray crystallographic, MS, **NMR** spectroscopic, and kinetic studies of the mechanisms of inhibition indicate that different intermediates or transition states are being represented that are dependent on the conditions of measurement and the specific groups flanking the carbonyl in the inhibitor. The species observed crystallographically are most consistent with tetrahedral intermediates that may be close approximations of those that occur during **substrate** hydrolysis. Initial kinetic studies suggest the possibility of irreversible and reversible active-site modification. Representative inhibitors have demonstrated antiresorptive activity both in vitro and in vivo and therefore are promising leads for therapeutic agents for the treatment of osteoporosis. Expansion of these inhibitor

concepts can be envisioned for the many other cysteine proteases implicated for therapeutic intervention.

=> d his

(FILE 'HOME' ENTERED AT 12:01:51 ON 21 OCT 2004)

FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS, WPIDS' ENTERED AT 12:02:06 ON 21 OCT 2004

L1 86252 S NMR AND (SUBSTRATE OR LIGAND OR PRODUCT)
L2 64621 S NMR AND (SUBSTRATE OR LIGAND OR ENZYME)
L3 49788 S L1 AND L2
E BRIAND JACQUES/IN
E BRIAND JACQUES/AU
L4 24 S E3
L5 3 S L4 AND L1
L6 2 DUP REM L5 (1 DUPLICATE REMOVED)

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	36.86	37.07
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.70	-0.70

FILE 'STNGUIDE' ENTERED AT 12:08:13 ON 21 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Oct 15, 2004 (20041015/UP).

=> logoff y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.54	37.61
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.70

STN INTERNATIONAL LOGOFF AT 12:13:39 ON 21 OCT 2004